netarsudil (Rhopressa)
Jump to navigation
Jump to search
Indications
- open-angle glaucoma
- used in combination with latanoprost (Rocklatan)
Dosage
- one drop in each eye in the evening
Ophthalmic 0.02% 2.5 mL
Storage
- store at 2-8 C (36-46 F) until opened
- after opening, the product may be kept at 2-25 C for up to 6 weeks or 2-8 C until the expiration date stamped on the bottle
Adverse effects
- conjunctival hyperemia (52)
- conjunctiveal hemorrhage
- corneal verticillata
- reticular epithelial corneal edema[4]
Mechanism of action
- Rho kinase inhibitor & norepinephrine transport inhibitor
- unlike other therapies to lower intraocular pressure (IOP), netarsudil appears to decrease episcleral venous pressure in addition to its primary IOP-lowering mechanism of increased trabecular meshwork outflow
- lowers intraocular pressure 4 mm Hg
More general terms
Component of
References
- ↑ Bankhead C Rho Kinase Drug Matches Timolol for IOP Control Similar efficacy at 3 and 6 months MedPage Today. October 14, 2017
Bacharach J, et al A double-masked, randomized, multicenter, active-controlled, parallel group, 6-month study assessing the ocular hypotensive efficacy and safety of netarsudil ophthalmic solution, 0.02% QD compared to timolol maleate ophthalmic solution, 0.5% BID AAOPT 2017; Abstract 170098 - ↑ Windle ML. FDA New Drug and Biologic Approvals -- 2017 Year-in-Review Medscape - Jan 11, 2018. https://reference.medscape.com/viewarticle/890871
U.S. Food and Drug Administration. Novel Drug Approvals for 2017. https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugInnovation/ucm537040.htm - ↑ Serle JB, Katz LJ, McLaurin E et al Two Phase 3 clinical trials comparing the safety and efficacy of netarsudil to timolol in patients with elevated intraocular pressure. Am J Ophthalmol. 2017 Nov 30. pii: S0002-9394(17)30513-5. PMID: https://www.ncbi.nlm.nih.gov/pubmed/29199013 Free Article
- ↑ 4.0 4.1 Chen TC, Jurkunas U, Chodosh J. A Patient With Glaucoma With Corneal Edema. JAMA Ophthalmol. 2020;138(8):917-918 PMID: https://www.ncbi.nlm.nih.gov/pubmed/32584374 https://jamanetwork.com/journals/jamaophthalmology/fullarticle/2767412
- ↑ HIGHLIGHTS OF PRESCRIBING INFORMATION RHOPRESSA<TM> (netarsudil ophthalmic solution) 0.02% https://rhopressa.com/assets/pdf/RHOPRESSA-Prescribing-Information.pdf